In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir

Protoplasma

Volumn 250, Issue 1, 2013, Pages 197-207

  Karthick, V ^a   Shanthi, V ^a   Rajasekaran, R ^a   Ramanathan, K ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Molecular docking; Molecular dynamic simulation; Neuraminidase; Normal mode analysis; Oseltamivir resistance

Indexed keywords

EID: 84873077420     PISSN: 0033183X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00709-012-0394-6     Document Type: Article

References (46)

1. Alexandrov V, Lehnert U, Echols N, Milburn D, Engelman D, Gerstein M (2005) Normal modes for predicting protein motions: a comprehensive database assessment and associated Web tool. Protein Sci 14(3): 633-643.
2. Alves ID, Bechara C, Walrant A, Zaltsman Y, Jiao CY, Sagan S (2011) Relationships between membrane binding, affinity and cell internalization efficacy of a cell-penetrating peptide: penetratin as a case study. PLoS One 6(9): e24096.
3. Baum SG (2009) Oseltamivir resistance: what does it mean clinically? Clin Infect Dis 49(12): 1836-1837.
4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28(1): 235-242.
5. Bucher DJ, Kilbourne ED (1972) A 2 (N2) neuraminidase of the X-7 influenza virus recombinant: determination of molecular size and subunit composition of the active unit. J Virol 10(1): 60-66.
6. Carlson HA, McCammon JA (2000) Accommodating protein flexibility in computational drug design. Mol Pharmacol 57(2): 213-218.
7. Cavasotto CN, Kovacs JA, Abagyan RA (2005) Representing receptor flexibility in ligand docking through relevant normal modes. J Am Chem Soc 127(26): 9632-9640.
8. Choudhury D, Biswas S, Roy S, Dattagupta JK (2010) Improving thermostability of papain through structure-based protein engineering. Protein Eng Des Sel 23(6): 457-467.
9. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453(7199): 1258-1261.
10. Colman PM, Varghese JN, Laver WG (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303(5912): 41-44.
11. Darden T, Perera L, Li L, Pedersen L (1999) New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Structure 7(3): 55-60.
12. Delarue M, Dumas P (2004) On the use of low-frequency normal modes to enforce collective movements in refining macromolecular structural models. Proc Natl Acad Sci U S A 101(18): 6957-62.
13. Du QS, Wang SQ, Chou KC (2007) Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem Biophys Res Commun 354(3): 634-640.
14. Feldman J, Snyder KA, Ticoll A, Pintilie G, Hogue CW (2006) A complete small molecule dataset from the protein data bank. FEBS Lett 580(6): 1649-1653.
15. Gasteiger J, Rudolph C, Sadowski J (1990) Automatic generation of 3D-atomic coordinates for organic molecules. Tetrahedron Comput Meth 3: 537-547.
16. Gubareva LV, Kaiser L, Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 355(9206): 827-835.
17. Hess B, Kutzner C, Spoel D, Lindahl E (2008) GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4(3): 435-447.
18. Hinkle A, Tobacman LS (2003) Folding and function of the troponin tail domain. Effects of cardiomyopathic troponin T mutations. J Biol Chem 278(1): 506-513.
19. Hsieh YC, Wu TZ, Liu DP, Shao PL, Chang LY, Lu CY, Lee CY, Huang FY, Huang LM (2006) Influenza pandemics: past, present and future. J F Med Assoc 105(1): 1-6.
20. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119(4): 681-690.
21. Lander GC, Evilevitch A, Jeembaeva M, Potter CS, Carragher B, Johnson J (2008) Bacteriophage lambda stabilization by auxiliary protein gpD: timing, location, and mechanism of attachment determined by cryo-EM. Structure 16(9): 1399-406.
22. Lindahl E, Hess B, van der Spoel D (2001) GROMACS 3. 0: a package for molecular simulation and trajectory analysis. J Mol Mod 7(8): 306-317.
23. Lopez G, Valencia A, Tress ML (2007) firestar-prediction of functionally important residues using structural templates and alignment reliability. Nucleic Acids Res 35: 573-577.
24. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk H (2004) Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78(22): 12665-12667.
25. McKimm-Breschkin JL (2000) Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res 47(1): 1-17.
26. Meagher KL, Carlson HA (2005) Solvation influences flap collapse in HIV-1 protease. Proteins: Struct Func Bioinf 58(1): 119-125.
27. Moscona A (2005) Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 353(25): 2633-2636.
28. Mukhtar MM, Rasool ST, Song D, Zhu C, Hao Q, Zhu Y, Wu J (2007) Origin of highly pathogenic H5N1 avian influenza virus in China and genetic characterization of donor and recipient viruses. J Gen Virol 88(11): 3094-3099.
29. Pales PS (2004) Influenza: old and new threats. Nat Med 10: 82-87.
30. Parthasarathy S, Murthy MR (2000) Protein thermal stability: insights from atomic displacement parameters (B values). Protein Eng 13(1): 9-13.
31. Rajasekaran R, George Priya Doss C, Sudandiradoss C, Ramanathan K, Purohit R, Sethumadhavan R (2008) Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach. C R Biol 331(6): 409-417.
32. Ringe D, Petsko GA (1986) Study of protein dynamics by X-ray diffraction. Methods Enzymol 131: 389-433.
33. Rungrotmongkol T, Udommaneethanakit T, Malaisree M, Nunthaboot N, Intharathep P, Sompornpisut P, Hannongbua S (2009) How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? Biophys Chem 145(1): 29-36.
34. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443(7107): 45-49.
35. Shirvan AN, Moradi M, Aminian M, Madani R (2007) Preparation of neuraminidase-specific antiserum from the H9N2 subtype of avian influenza virus Turk. J Vet Anim 31(4): 219-223.
36. Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ (2005) GROMACS: fast, flexible, and free. Comput Chem 26(16): 1701-1718.
37. Su Y, Yang HY, Zhang BJ, Jia HL, Tien P (2008) Analysis of a point mutation in H5N1 avian influenza virus hemagglutinin in relation to virus entry into live mammalian cells. Arch Virol 153(12): 2253-2261.
38. Suhre K, Sanejouand YH (2004) ElNemo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement. Nucleic Acids 32: 610-614.
39. Takeda M, Leser GP, Russell CJ, Lamb RA (2003) Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc Natl Acad Sci 100(25): 14610-14617.
40. Teague SJ (2003) Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2(7): 527-541.
41. Thompson MA (2004) ArgusLab 4. 0. 1. Planaria Software, Seattle. http://www. ArgusLab. com.
42. Thompson MA (2004b) Poster presentation: molecular docking using arguslab: An efficient shape-based search algorithm and the AScore scoring function. Fall ACS meeting, Philadelphia.
43. Varghese JN, Smith PW, Sollis SL, Blick SJ, Sahasrabudhe A, Mckimm-Breschkin JL, Colman PM (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6(6): 735-746.
44. Von Itzstein M, Wu WY, Kok BG, Pegg MS, Dyason JC, Jin B, van Phan T, Smythe ML, White HF, Oliver SW (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363(6428): 418-423.
45. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8(2): 127-134.
46. Yuan Z, Bailey TL, Teasdale RD (2005) Prediction of protein B-factor profiles. Proteins 58(4): 905-912.